<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944045</url>
  </required_header>
  <id_info>
    <org_study_id>P150961</org_study_id>
    <secondary_id>2016-002275-10</secondary_id>
    <nct_id>NCT02944045</nct_id>
  </id_info>
  <brief_title>Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients</brief_title>
  <acronym>PIC</acronym>
  <official_title>Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pneumocystis jiroveci pneumonia (PcP) increased in non HIV immunocompromised patients.&#xD;
      Mortality remains high for those patients with comorbidities (50% for patients with the most&#xD;
      severe Pneumocystis pneumonia). Physiopathology, characteristics and outcome of PcP in&#xD;
      non-HIV patients remains different from those in HIV patients. Steroids in HIV patients with&#xD;
      PcP has been associated with decreased mortality but in non-HIV patients, adjunctive steroids&#xD;
      remains controversy. Some retrospective studies in that field did not find any beneficial&#xD;
      effects of steroids ((1mg/kg/jour d'Equivalent Prednisone (EP)). However, all the studies&#xD;
      were retrospective, non randomised studies including various underlying disease and severity&#xD;
      of PcP was variable. Moreover, dosage and delay of steroids were variable leading difficult&#xD;
      to interpret all the results.&#xD;
&#xD;
      The investigators want to demonstrate the beneficial effect of steroid during PcP in non-HiV&#xD;
      immunocompromised patients with a double blinded randomised clinical trials comparing&#xD;
      adjunctive steroids to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>28 days mortality after the randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>90 days mortality after the randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Day 120</time_frame>
    <description>Mortality at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>For patients admitted to ICU at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory failure</measure>
    <time_frame>Day 28</time_frame>
    <description>Acute respiratory failure during treatment defined by one of those criteria within 28 days :&#xD;
Increased need of oxygen (more than 9 l/min of high flow nasal oxygen with Inspired Fraction of Oxygen (fiO2) &gt;50%)&#xD;
Admission to ICU after randomisation&#xD;
Need of mechanical ventilation (invasive or non invasive) or high flow nasal oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Duration of mechanical ventilation invasive and/or non invasive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of septic shock</measure>
    <time_frame>Day 28</time_frame>
    <description>septic shock is defined as need for vasopressor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>Day 28</time_frame>
    <description>KDIGO score &gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital acquired infectious disease</measure>
    <time_frame>Day 28</time_frame>
    <description>Global incidence incidence of infections. Incidence of pulmonary or extra-pulmonary infections.&#xD;
Incidence of bacterial, viral and fungal infections. Diagnosis of infectious disease will be defined by the need of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Day 120</time_frame>
    <description>Hospital length of stay at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Day 90</time_frame>
    <description>ICU length of stay at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Insulin treatment</measure>
    <time_frame>Day 28</time_frame>
    <description>Insulin treatment is defined :&#xD;
patient without insulin treatment before study : start of insulin therapy&#xD;
patient treated with insulin before study : increased dose (&gt;30%) of insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Pneumocystis</condition>
  <condition>Steroids</condition>
  <condition>Immunocompromised Patient</condition>
  <condition>Hematologic Neoplasms</condition>
  <condition>Immunosuppressive Agents</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline serum, same volume as in the Experimental arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone intra veinous&#xD;
Day 1 to 5 : 30mg twice per day&#xD;
Day 6 to 10 : 30mg per day&#xD;
Day 11 to 21 : 20mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone intra veinous&#xD;
Day 1 to 5 : 30mg twice per day&#xD;
Day 6 to 10 : 30mg per day&#xD;
Day 11 to 21 : 20mg per day</description>
    <arm_group_label>Steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>saline serum</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Severe PcP : 1 / interstitial acute pneumonia with possible or typical criteria for&#xD;
             PcP and positive specimen for Pneumocystis jirovecii (excluding PCR) ; or interstitial&#xD;
             acute pneumonia with typical criteria for PcP and positive PCR in respiratory&#xD;
             specimen. 2/ Arterial pression of Oxygen (PaO2) &lt; 60 mmHg on room air need of 3 L/min&#xD;
             oxygen for saturation &gt;92% or tachypnea&gt;30min need of mechanical ventilation for acute&#xD;
             respiratory failure.&#xD;
&#xD;
          -  Treatment for PcP started for less than 7 days.&#xD;
&#xD;
          -  Non-HIV immunosuppression : malignant hematological disease, solid tumor cured for&#xD;
             less than 5 years, allogenic stem cell transplant, Steroids (&gt;0.3mg/kg equivalent&#xD;
             prednisone for more than 3 weeks or &gt; 20mg/days for more than one months) or other&#xD;
             immunosuppressive treatment for more than one months or solid organ transplantation.&#xD;
&#xD;
          -  Signed inform consent by patient or relatives&#xD;
&#xD;
          -  Health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV Serology HIV 1 or 2 positive&#xD;
&#xD;
          -  Need of steroid ≥1mg/kg/j equivalent prednisone for another pathology (acute Graft&#xD;
             versus Host disease (GVH= for example)&#xD;
&#xD;
          -  Contra-indication for steroids&#xD;
&#xD;
          -  Pregnancy of breath-feeding&#xD;
&#xD;
          -  Denied to participate&#xD;
&#xD;
          -  No health insurance&#xD;
&#xD;
          -  tutelage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginie Lemiale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elie Azoulay, MD PHD</last_name>
    <role>Study Director</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie Lemiale, MD</last_name>
    <phone>142499419</phone>
    <phone_ext>+33</phone_ext>
    <email>virginie.lemiale@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu Resche-Rigon, MD PHD</last_name>
    <phone>142499742</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical ICU</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>virginie lemiale, MD</last_name>
      <phone>142499419</phone>
      <phone_ext>+33</phone_ext>
      <email>virginie.lemiale@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

